ST Renfu's RFUS-949 Tablets Enter Phase II Clinical Trial
ST Renfu (600079) announced on September 3 that its drug candidate RFUS-949 tablets, intended for the treatment of acute and chronic pain, has entered a Phase II clinical trial. The trial aims to preliminarily evaluate the drug's efficacy and safety, providing a basis for subsequent Phase III studies and marking further progress in the drug's development.
The drug candidate is intended for the treatment of acute and chronic pain.
The entry of RFUS-949 tablets into Phase II clinical trials marks further progress in the drug's research and development process. Clinical trials are a critical stage in drug development, and the primary objective of Phase II trials is to preliminarily evaluate the drug's efficacy and safety, providing a basis for subsequent Phase III clinical trials.